Document Detail

Early intervention for treatment and prevention of colorectal carcinomatosis: a plan for individualized care.
MedLine Citation:
PMID:  23021724     Owner:  NLM     Status:  MEDLINE    
The benefits that are reported in patients who have carcinomatosis from colorectal cancer increase as the extent of disease within the abdomen and pelvis decreases. To optimize treatments that involve cytoreductive surgery and perioperative chemotherapy, early intervention is necessary. Strategies to improve the results of carcinomatosis treatments include second-look surgery and hyperthermic intraperitoneal chemotherapy in patients at high risk for recurrence. Alternatively, the use of hyperthermic intraperitoneal chemotherapy can be used to treat or prevent carcinomatosis at the time of primary colorectal cancer resection in selected patients.
Paul H Sugarbaker
Related Documents :
25103004 - Aims of combined modality therapy in rectal cancer (m0).
23450004 - The role of local excision in invasive adenocarcinoma of the ampulla of vater.
22199314 - The emt status in the primary tumor does not predict postoperative recurrence or diseas...
23195204 - Racial disparities in surgical resection and survival among elderly patients with poor ...
10376284 - Sense organs in post-embryonic stages of hyalomma marginatum marginatum koch, 1844 (aca...
10439364 - Limited stage i and ii follicular non-hodgkin's lymphoma: the nebraska lymphoma study g...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Surgical oncology clinics of North America     Volume:  21     ISSN:  1558-5042     ISO Abbreviation:  Surg. Oncol. Clin. N. Am.     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-10-01     Completed Date:  2013-03-05     Revised Date:  2013-04-15    
Medline Journal Info:
Nlm Unique ID:  9211789     Medline TA:  Surg Oncol Clin N Am     Country:  United States    
Other Details:
Languages:  eng     Pagination:  689-703     Citation Subset:  IM    
Copyright Information:
Copyright © 2012 Elsevier Inc. All rights reserved.
Program in Peritoneal Surface Malignancy, Washington Cancer Institute, Washington, DC 20010, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents / therapeutic use*
Carcinoma / drug therapy*,  pathology,  surgery
Chemotherapy, Cancer, Regional Perfusion / methods*
Colorectal Neoplasms / drug therapy*,  pathology,  surgery
Disease Progression
Early Medical Intervention
Hyperthermia, Induced / methods*
Individualized Medicine
Infusions, Parenteral*
Patient Care Planning
Peritoneal Neoplasms / drug therapy*,  secondary,  surgery
Second-Look Surgery / methods
Time Factors
Reg. No./Substance:
0/Antineoplastic Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Randomized clinical trials for colorectal cancer peritoneal surface malignancy.
Next Document:  Do the biomechanical properties of the ankle-foot complex influence postural control for people with...